Gold stocks to beat market volatility
Gold stocks to beat market volatility
Imugene Onboards Leading Surgical Oncologist to OV SAB; Completes $24.6 million placement

Imugene Onboards Leading Surgical Oncologist to OV SAB; Completes $24.6 million placement

  • Dec 10, 2019 AEDT
  • Team Kalkine

Australia-based clinical stage immuno-oncology player, Imugene Limited (ASX: IMU) has recently announced the appointment of Surgeon Scientist, Dr. Rebecca Auer to its newly formed OV (oncolytic virotherapy) Scientific Advisory Board. Dr. Auer is t...

Imugene Received Oversubscribed Placement Commitments to Raise $24.6 Million

Imugene Received Oversubscribed Placement Commitments to Raise $24.6 Million

  • Dec 03, 2019 AEDT
  • Team Kalkine

Clinical-stage immuno-oncology player, Imugene Limited (ASX: IMU) recently notified that it has received firm commitments for a capital raising of up to $24.6 million that involves Placement of up to 683 million ordinary shares to sophisticated and p...

Imugene Announces Completion of Clinical Grade GMP Batches by CF33 Oncolytic Virus Constructs

Imugene Announces Completion of Clinical Grade GMP Batches by CF33 Oncolytic Virus Constructs

  • Nov 25, 2019 AEDT
  • Team Kalkine

In a recent ASX update, Australian headquartered Imugene Limited (ASX: IMU) has notified that CF33 oncolytic virus CheckVacc and Vaxinia constructs have completed clinical grade GMP batches at the manufacturing facility, City of Hope Center for Biome...

Another Feather in Imugene’s Cap; Completes Acquisition of Oncolytic Virus CF33

Another Feather in Imugene’s Cap; Completes Acquisition of Oncolytic Virus CF33

  • Nov 19, 2019 AEDT
  • Team Kalkine

Imugene Limited (ASX: IMU) jumped 18 per cent on ASX following the completion of oncolytic virus CF33 and Vaxinia Pty Ltd acquisition on 18th November 2019. IMU closed the trading session at $0.053 with ~259 million shares in rotation on 18th Novemb...

Biotech player, Imugene Soars 27% on ASX; Glance Through Key Developments

Biotech player, Imugene Soars 27% on ASX; Glance Through Key Developments

  • Nov 11, 2019 AEDT
  • Team Kalkine

Clinical-stage biotech player Imugene Limited (ASX: IMU) soared ~27 per cent on the ASX today, settling the day?s trade at $0.033 on 11th November 2019. The stock has delivered a substantial return of ~53 per cent in the last six months, driven by si...

Imugene Limited Receives $4.13 Million R&D Tax Refund from Australian Government

Imugene Limited Receives $4.13 Million R&D Tax Refund from Australian Government

  • Nov 06, 2019 AEDT
  • Team Kalkine

Australian immuno-oncology company, Imugene Limited (ASX: IMU) is developing a pipeline of mimotope-based B-cell immunotherapies against oncology targets that could replace or be used in combination with monoclonal antibodies. The company intends to ...

Lens through Imugene’s September 2019 Quarterly 4C Report

Lens through Imugene’s September 2019 Quarterly 4C Report

  • Oct 29, 2019 AEDT
  • Team Kalkine

Biotechnology firm headquartered in Australia, Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology player that develops novel immunotherapies to treat and eradicate cancerous tumours. The company?s unique platform technologies hold the pot...

Imugene Commends City of Hope Researchers on Receiving US Department of Defense Grant

Imugene Commends City of Hope Researchers on Receiving US Department of Defense Grant

  • Oct 24, 2019 AEDT
  • Team Kalkine

As per latest update from Imugene Limited (ASX: IMU), the prominent City of Hope researchers have received a Grant of USD 564,173 from the US Department of Defense to study the company?s Oncolytic Virotherapy (OV) CF33 in gastric cancer. Marking a s...

Imugene Released Program Update on Oncolytic Virus CF33’s Phase 1 Clinical Trial Plans

Imugene Released Program Update on Oncolytic Virus CF33’s Phase 1 Clinical Trial Plans

  • Oct 23, 2019 AEDT
  • Team Kalkine

ASX-listed clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) has released an update on the preliminary clinical development plan for the intended exclusive license of the patents encompassing the oncolytic virus technology, CF33. The co...

Imugene Hires Professor Yuman Fong to Lead Oncolytic Virotherapy Scientific Advisory Board

Imugene Hires Professor Yuman Fong to Lead Oncolytic Virotherapy Scientific Advisory Board

  • Oct 21, 2019 AEDT
  • Team Kalkine

Australia-based clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is involved in the development of various new and novel immunotherapies that attempt to stimulate the patient?s immune system to eradicate and treat tumours. Imugene?s un...

Register Now

Get a call back now to get stock recommendations

x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK